Señales en vivo de 5CV.F | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 15:42):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
Volumen de hoy	26 387.00
Volumen promedio	14 349.00
Capitalización de mercado	480.01M
EPS	€-0.217 ( 2023-09-30 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.460
ATR14	€0.0250 (1.16%)

CureVac N.V. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CureVac N.V. Finanzas

Annual	2023
Ingresos:	€52.66M
Beneficio Bruto:	€-91.08M (-172.97 %)
EPS:	€-1.150

FY	2023
Ingresos:	€52.66M
Beneficio Bruto:	€-91.08M (-172.97 %)
EPS:	€-1.150

FY	2022
Ingresos:	€67.42M
Beneficio Bruto:	€-116.57M (-172.91 %)
EPS:	€-1.320

FY	2021
Ingresos:	€102.99M
Beneficio Bruto:	€-135.21M (-131.28 %)
EPS:	€-2.34

Financial Reports:

No articles found.

CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.